Completed PHASE1 INTERVENTIONAL 1-arm NCT02118285

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Sponsor: Incyte Corporation

Conditions Fallopian Tube Carcinoma Ovarian Cancer Primary Peritoneal Carcinoma

Interventions Cyclophosphamide Fludarabine IL-2 INCB024360 NK cells

Updated 7 times since 2017 Last updated: Dec 3, 2017 Started: Jul 28, 2014 Primary completion: Nov 12, 2015 Completion: Nov 12, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Fallopian Tube Carcinoma and Ovarian Cancer and is currently completed. Incyte Corporation leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Suspended → Completed

▶ Show 2 earlier versions

Feb 2017 — Sep 2017 [monthly]

Suspended PHASE1
Jan 2017 — Feb 2017 [monthly]

Suspended PHASE1

First recorded

Jul 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation
Masonic Cancer Center, University of Minnesota

Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States